Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Revenue | $5 | $7 | $10 | $7 |
| % Growth | -26% | -25.6% | 31% | – |
| Cost of Goods Sold | $2 | $2 | $3 | $3 |
| Gross Profit | $3 | $5 | $7 | $4 |
| % Margin | 60.2% | 68.8% | 68.7% | 56.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $7 | $10 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $8 | $10 | $10 |
| Operating Income | -$2 | -$3 | -$4 | -$6 |
| % Margin | -38.6% | -36.7% | -40.2% | -84.1% |
| Other Income/Exp. Net | -$1 | -$1 | $0 | -$7 |
| Pre-Tax Income | -$3 | -$4 | -$4 | -$13 |
| Tax Expense | $0 | $0 | $6 | -$3 |
| Net Income | -$3 | -$4 | -$9 | -$10 |
| % Margin | -57.9% | -54.8% | -97.7% | -131.4% |
| EPS | -0.11 | -0.15 | -0.39 | -0.43 |
| % Growth | 26.7% | 61.5% | 9.3% | – |
| EPS Diluted | -0.11 | -0.15 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 27 | 26 | 24 | 22 |
| Weighted Avg Shares Out Dil | 27 | 26 | 24 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$3 | -$10 |
| % Margin | -31.6% | -30.9% | -35.9% | -138.9% |